Premium
A pilot study on the effects of hormonal contraceptives on beta‐arrestin1 levels in peripheral blood mononuclear leukocytes
Author(s) -
Smith Keisha,
Rana Tanu,
Archibong Anthony E.,
Nayyar Tultul
Publication year - 2018
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.2018.32.1_supplement.880.3
Subject(s) - medicine , progestin , depression (economics) , biomarker , luteal phase , physiology , hormone , peripheral blood mononuclear cell , biochemistry , chemistry , in vitro , economics , macroeconomics
OBJECTIVE Women are twice as likely as likely as men to develop depression during reproductive years. Use of hormonal contraceptives, during reproductive years, may be causal with development of depression in a subgroup of women because observational studies indicate an association between use of progestin (Depo‐Provera) and development of depressive symptoms. Previously we have reported reduced levels of beta arrestin 1(β‐AR‐1) during premenstrual depressive disorder, may be a potential biomarker of depression. In this study we compared the β‐AR‐1 protein levels and the Hamilton Depression Rating Scores (HDRS) as well, in women on non‐hormonal contraceptives (control), combine‐only contraceptives (COC), and progestin‐only contraceptives (POC). METHODS Study participants (n=29) were non‐pregnant women between 18–42 years of age, not taking any antidepressants/therapy and at the luteal phase of menstruation. The participants were evaluated with Neuropsychiatric Interview (DSMIV‐TR). The severity of depression were determined by the HDRS. The protein levels of beta‐arrestin1 in the in peripheral blood mononuclear leukocytes (PBMC) were determined by ELISA. RESULTS The magnitude of the different parameters for Axis 1 mental disorders were significantly higher and beta arrestin1 protein levels in PBMC were significantly lower in women currently using progestin‐only contraceptives as compared to the control. CONCLUSION These findings indicate the possibility of reduced levels of β‐AR‐1 and associated symptoms of depression in a subgroup of women may results from the use of POC. Support or Funding Information Clinical Research Education and Career Development in Minority R25RR17577 (NCRR/NIMHD) and U54 MD007593 (NIMHD) and U54 RR026140 (NCRR) at NIH. This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .